This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Pertuzumab for breast cancer metastatic, HER2 positive – first line

< Back

Pertuzumab for breast cancer metastatic, HER2 positive – first line


Cancer and Palliative Care

December 2010

Pertuzumab (2C4 antibody; R-1273; rhuMAb2C4) is a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2). Pertuzumab is the first in a new class of anticancer agents called HER dimerisation inhibitors. Pertuzumab binds to the HER2 receptor and prevents the pairing (dimerisation) of HER2 with other HER family receptors, inhibiting intracellular signalling. Pertuzumab and trastuzumab bind to different regions of HER2 and may potentially provide synergistic activity. In trials, pertuzumab was administered by intravenous (IV) infusion with a loading dose of 840mg followed by 420mg every three weeks in combination with trastuzumab and docetaxel.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts